Veracyte (VCYT) Stock Price, News & Analysis

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VCYT shares.
View VCYT analyst ratings or view top-rated stocks.

5 analysts have issued twelve-month price targets for Veracyte's shares. Their VCYT share price targets range from $21.00 to $34.00. On average, they anticipate the company's share price to reach $29.00 in the next twelve months. This suggests a possible upside of 49.1% from the stock's current price.
View analysts price targets for VCYT or view top-rated stocks among Wall Street analysts.

Veracyte's stock was trading at $27.51 at the beginning of 2024. Since then, VCYT shares have decreased by 29.3% and is now trading at $19.45.
View the best growth stocks for 2024 here.

Veracyte saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,640,000 shares, an increase of 32.8% from the March 15th total of 2,740,000 shares. Based on an average trading volume of 633,600 shares, the days-to-cover ratio is presently 5.7 days.
View Veracyte's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our VCYT earnings forecast.

Veracyte, Inc. (NASDAQ:VCYT) issued its quarterly earnings results on Thursday, February, 22nd. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.03. The biotechnology company earned $98.20 million during the quarter, compared to analysts' expectations of $95.49 million. Veracyte had a negative trailing twelve-month return on equity of 2.02% and a negative net margin of 20.61%.

ETFs with the largest weight of Veracyte (NASDAQ:VCYT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Global X Telemedicine & Digital Health ETF (EDOC), ARK Genomic Revolution ETF (ARKG), Invesco Biotechnology & Genome ETF (PBE), ROBO Global Healthcare Technology and Innovation ETF (HTEC), ARK Innovation ETF (ARKK), WisdomTree BioRevolution Fund (WDNA) and ARK Next Generation Internation ETF (ARKW).

Veracyte issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $394.0 million-$402.0 million, compared to the consensus revenue estimate of $393.3 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

Veracyte's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (4.46%), AMI Asset Management Corp (0.27%), Diversified Trust Co (0.03%), Los Angeles Capital Management LLC (0.03%), Artemis Investment Management LLP (0.01%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John L Bishop, Karin Eastham, Marc Stapley and Muna Bhanji.
View institutional ownership trends.

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.